Rite Aid launches Rite Track Diabetes Tour
CAMP HILL, Pa. — Rite Aid is collaborating with LifeScan to bring free diabetes testing, resources and materials to communities across the Northeast, the retail pharmacy chain said Friday.
The Rite Track Diabetes Tour will start in New York on Tuesday at 11 a.m. to mark American Diabetes Month. Chef Sam Talbot, who has Type 1 diabetes, will be aboard the bus to share his diabetes story and give away signed copies of his newly published cookbook, "The Sweet Life: Diabetes Without Boundaries."
At every tour stop, attendees can step into the bus for a complimentary blood-glucose test to help identify their risk for developing diabetes or an A1C test, which shows a person living with diabetes their average blood glucose over the past three months. They also can speak with a Rite Aid pharmacist about their test results and learn about Rite Aid’s resources for people with diabetes. The 30 stops on the tour also will include Boston; Philadelphia; Washington; Pittsburgh; Harrisburg, Pa.; Buffalo, N.Y.; and Norfolk, Va.
"The Rite Track Diabetes Tour is a great way for us to offer additional support to people with diabetes, whether they’ve been living with diabetes forbears or have just recently been diagnosed," Rite Aid EVP pharmacy Robert Thompson said. "We want them to know they aren’t alone and that their Rite Aid pharmacists can help them successfully manage and live well with diabetes."
In addition, Rite Aid’s philanthropic arm, the Rite Aid Foundation, will donate a total of $20,000 to local American Diabetes Association chapters.
Pfizer completes Icagen acquisition
NEW YORK — Icagen officially is a wholly owned subsidiary of Pfizer.
As part of the transaction, which first was announced in July, Icagen now will be part of Pfizer’s worldwide research and development organization and also will be integrated into Neusentis, Pfizer’s pain, sensory disorders and regenerative medicine research unit.
The aggregate transaction value, which includes the value of the shares that already were owned by Pfizer, was about $56 million.
“We’re excited that Icagen, a global leader in pain research, has now joined Pfizer,” said Ruth McKernan, Pfizer SVP and chief scientific officer of Neusentis. “We have worked closely with Icagen for several years and have the utmost respect for their expertise. Their understanding of ion channel mechanisms will enhance our ability to develop novel drugs for the treatment of pain and related disorders.”
Prevent Blindness America debuts diabetic eye disease awareness campaign
CHICAGO — A volunteer eye health and safety organization has introduced a new program that seeks to educate the public on the potential effects diabetes may have on one’s vision.
Prevent Blindness America said its "Live Right, Save Sight!" campaign provides free information on diabetic eye disease — including such complications as diabetic retinopathy, an eye disease that weakens the small blood vessels in the retina — including risk factors, treatment options and Medicare benefits, as well as a dedicated Web page at PreventBlindness.org/diabetes. The organization also outlines recommendations to diabetics on ways to maintain their eye sight.
"The diabetes epidemic that we are facing is very serious and the resulting complications from this disease can be devastating to our health," Prevent Blindness America president and CEO Hugh Parry said. "The good news is that by making a committed effort to leading a healthy lifestyle today, we can help delay or even prevent developing diabetes and its effects in the future."